June 27 — In a major scientific breakthrough, researchers at Johns Hopkins University have demonstrated that gene therapy could provide a durable and long-lasting treatment for HIV. The study, recently published in Nature Communications, shows that a specially engineered molecule can block HIV from entering immune cells, potentially transforming the future of HIV care.
The research focuses on a naturally occurring peptide molecule known as EPI-X4, which was modified to enhance its ability to block CXCR4 — a key receptor that HIV uses to infect immune cells. The scientists found that when this optimized molecule was delivered via gene therapy, it significantly reduced the virus’s ability to spread.
“Our study suggests that this form of gene therapy can offer a long-lasting defense against HIV infection by modifying the host’s own cells,” said Dr. Mathias Lichterfeld, co-author of the study and an infectious disease expert. “This has the potential to fundamentally change the way HIV is treated.”
The current standard of care for HIV involves lifelong use of antiretroviral therapy (ART), which, while effective in suppressing the virus, does not eliminate it and can cause long-term side effects. Gene therapy presents a different approach by targeting the body’s own biology to resist infection.
In the study, researchers used a gene therapy vector to insert the optimized EPI-X4 gene into hematopoietic stem cells. These modified cells were then able to produce immune cells resistant to HIV infection. The effects of the therapy were shown to last for several weeks in preclinical models, indicating a potentially durable and sustainable treatment option.
Scientists believe that this therapy could offer significant benefits over conventional treatments, especially for patients who face challenges with daily ART adherence. If successful in human trials, it could also reduce the long-term costs and health complications associated with current HIV treatment regimens.
Dr. Gero Hütter, the physician who performed the first known case of HIV cure via bone marrow transplant in 2007, called the study “a significant step forward” in the global effort to find a functional cure for HIV.
While further research and human trials are needed, the findings have generated optimism in the medical community. The study marks a promising step toward a gene-based HIV therapy that could provide not just treatment, but possibly long-term viral remission.
